Alnylam Finds Partner For Liver Cancer Program In China’s Ascletis
This article was originally published in The Pink Sheet Daily
U.S.-China hybrid Ascletis is in-licensing rights to Phase II-ready RNA-interference program ALN-VSP from Alnylam with an eye on developing a groundbreaking therapy for an underserved indication that hits especially hard in China.
You may also be interested in...
In part two of this interview, the Alnylam chief executive discusses the thought process behind the biotech’s cutback in staff this past January and its $87 million cash raise in February.
The RNAi-pioneering biotech is sitting in a different position than it was a year ago, about to take its lead candidate into pivotal studies and with a new partnership with Arrowhead and $87 million in proceeds from one of the largest follow-on public offerings in recent memory by a biotech firm.
From offices in North Carolina and Hangzhou, the start-up will in-license compounds to sell in China while developing its own candidates.